News
PFE
26.18
+0.15%
0.04
Why Wall Street Is Dead Wrong About This Popular Stock
The Motley Fool · 6h ago
Pfizer Pivots to Obesity and Oncology as Wall Street Waits
TipRanks · 10h ago
Pfizer: Phase 3 Trial Shows TALZENNA + XTANDI Cut Progression Risk 52% In HRR-mutated MCSPC
NASDAQ · 13h ago
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Barchart · 18h ago
Pfizer’s US$10.5b Oncology Deal With Innovent And What It Means For Valuation
Simply Wall St · 20h ago
Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market
TipRanks · 1d ago
Pfizer’s Real-World Lung Cancer Study on Dacomitinib: What Investors Should Know
TipRanks · 1d ago
EU to target XFG variant for next COVID vaccines
Seeking Alpha · 1d ago
Cboe data shows mixed options sentiment in Pfizer with shares down 0.44%
TipRanks · 1d ago
FDA to cut animal testing in cancer drug development
Seeking Alpha · 1d ago
These 10 large-cap U.S. stocks rank among the market's cheapest names
Seeking Alpha · 1d ago
Healthcare ETFs to Buy as Eli Lily Steps Into Vaccine Market With $4B Bet
NASDAQ · 1d ago
Pfizer announces seven-year follow-up results from Phase 3 CROWN trial
TipRanks · 1d ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Healthcare Stocks Delivering High-Dividend Yields
Benzinga · 1d ago
Pfizer Reports Positive Seven-Year Follow-up Data For LORBRENA In Lung Cancer Trial
NASDAQ · 1d ago
Pfizer Announces Unprecedented 7-Yr Follow-Up Results From Phase 3 CROWN Trial Evaluating LORBRENA Vs XALKORI In People With ALK-Positive Advanced Or Metastatic NSCLC
Benzinga · 1d ago
FDA panel backs XFG strain for 2026-27 COVID vaccine update
Seeking Alpha · 1d ago
Pfizer and Innovent Join Forces to Develop 12 New Cancer Treatments Worldwide
Benzinga · 1d ago
Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies
Benzinga · 1d ago
Pfizer Enters Deal With Innovent Biologics To Co-Develop Oncology Medicines
NASDAQ · 1d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.